Here is what I have asked or should have asked (in no particular order):
1. Probability of local v. distant recurrence with your data
2. Area of salvage treatment (prostate bed v. full pelvic)
4. IMRT v. IGRT v. TomoTherapy
5. Salvage radiation v. radiation with ADT
6. If ADT, how long (6mo v. 2y)
Also, you may want to have your pathology slides re-examined by someone else. When they looked at my at MSK they found a focal EPE and two positive margines v. just one small positive margine. This made my decision easier as it makes local recurrence more likely.
From what I was told by multiple docs, the RT is really not a big deal. There are few sideeffects, they are mild and usually don't show up until last few weeks of the treatment.
Father died from poorly differentiated PCa @ 78 - normal PSA and DRE
5 biopsies over 4 years negative while PSA going from 3.8 to 28
Dx Nov 2007, age 46, PSA 29, Gleason 4+4=8
Decided to participate in clinical trial at Duke - 6 rounds of chemo (Taxotere+Avastin)
PSA prior to treatment on 1/8/2008 is 33.90, bounced on 1/31/2008 to 38.20, and down at the end of the treatment (4/24/2008) to 20.60
RRP at Duke (Dr. Moul) on 6/16/2008, Gleason downgraded 4+3=7, T3a N0MX, focal extraprostatic extension, two small positive margins
PSA undetectable for 8 months, then 2/6/2009-0.10, 4/26/2009-0.17, 5/22/2009-0.20, 6/11/2009-0.27
Salvage IMRT + 6 Months ADT: Casodex started 6/12/2009, Lupron 6/22/2009, PSA 6/25/2009-0.1, T=516, IMRT to start mid-Aug